文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

术前常规检查对pT2N0M0或pT3N0M0期结直肠癌患者预后的预测价值

Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer.

作者信息

Jing Peng-Fei, Chen Jin, Yu En-Da, Miao Chao-Yu

机构信息

Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai 200433, China.

Department of Endocrinology and Metabolism, Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai 200433, China.

出版信息

World J Gastrointest Oncol. 2024 Jun 15;16(6):2429-2438. doi: 10.4251/wjgo.v16.i6.2429.


DOI:10.4251/wjgo.v16.i6.2429
PMID:38994158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11236233/
Abstract

BACKGROUND: In recent years, the incidence of colorectal cancer (CRC) has been increasing. With the popularization of endoscopic technology, a number of early CRC has been diagnosed. However, despite current treatment methods, some patients with early CRC still experience postoperative recurrence and metastasis. AIM: To search for indicators associated with early CRC recurrence and metastasis to identify high-risk populations. METHODS: A total of 513 patients with pT2N0M0 or pT3N0M0 CRC were retrospectively enrolled in this study. Results of blood routine test, liver and kidney function tests and tumor markers were collected before surgery. Patients were followed up through disease-specific database and telephone interviews. Tumor recurrence, metastasis or death were used as the end point of study to find the risk factors and predictive value related to early CRC recurrence and metastasis. RESULTS: We comprehensively compared the predictive value of preoperative blood routine, blood biochemistry and tumor markers for disease-free survival (DFS) and overall survival (OS) of CRC. Cox multivariate analysis demonstrated that low platelet count was significantly associated with poor DFS [hazard ratio (HR) = 0.995, 95% confidence interval (CI): 0.991-0.999, = 0.015], while serum carcinoembryonic antigen (CEA) level (HR = 1.008, 95%CI: 1.001-1.016, = 0.027) and serum total cholesterol level (HR = 1.538, 95%CI: 1.026-2.305, = 0.037) were independent risk factors for OS. The cutoff value of serum CEA level for predicting OS was 2.74 ng/mL. Although the OS of CRC patients with serum CEA higher than the cutoff value was worse than those with lower CEA level, the difference between the two groups was not statistically significant ( = 0.075). CONCLUSION: For patients with T2N0M0 or T3N0M0 CRC, preoperative platelet count was a protective factor for DFS, while serum CEA level was an independent risk factor for OS. Given that these measures are easier to detect and more acceptable to patients, they may have broader applications.

摘要

背景:近年来,结直肠癌(CRC)的发病率一直在上升。随着内镜技术的普及,许多早期结直肠癌得以确诊。然而,尽管有目前的治疗方法,一些早期结直肠癌患者仍会出现术后复发和转移。 目的:寻找与早期结直肠癌复发和转移相关的指标,以识别高危人群。 方法:本研究回顾性纳入了513例pT2N0M0或pT3N0M0的结直肠癌患者。收集术前血常规、肝肾功能检查及肿瘤标志物的结果。通过疾病特异性数据库和电话访谈对患者进行随访。以肿瘤复发、转移或死亡作为研究终点,以寻找与早期结直肠癌复发和转移相关的危险因素及预测价值。 结果:我们全面比较了术前血常规、血液生化及肿瘤标志物对结直肠癌无病生存期(DFS)和总生存期(OS)的预测价值。Cox多因素分析表明,低血小板计数与DFS不良显著相关[风险比(HR)=0.995,95%置信区间(CI):0.991-0.999,P = 0.015],而血清癌胚抗原(CEA)水平(HR = 1.008,95%CI:1.001-1.016,P = 0.027)和血清总胆固醇水平(HR = 1.538,95%CI:1.026-2.305,P = 0.037)是OS的独立危险因素。预测OS的血清CEA水平截断值为2.74 ng/mL。虽然血清CEA高于截断值的结直肠癌患者的OS比CEA水平较低者差,但两组间差异无统计学意义(P = 0.075)。 结论:对于T2N0M0或T3N0M0的结直肠癌患者,术前血小板计数是DFS的保护因素,而血清CEA水平是OS的独立危险因素。鉴于这些指标更容易检测且患者更易接受,它们可能有更广泛的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ee/11236233/363337d84108/WJGO-16-2429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ee/11236233/363337d84108/WJGO-16-2429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ee/11236233/363337d84108/WJGO-16-2429-g001.jpg

相似文献

[1]
Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer.

World J Gastrointest Oncol. 2024-6-15

[2]
Early Postoperative Serum Carcinoembryonic Antigen Is a Stronger Independent Prognostic Factor for Stage II Colorectal Cancer Patients Than T4 Stage and Preoperative CEA.

Front Oncol. 2022-1-11

[3]
Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.

World J Gastroenterol. 2019-9-7

[4]
[Predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage II-III colorectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2015-9

[5]
Prognostic value of the ratio of carcinoembryonic antigen concentration to maximum tumor diameter in patients with stage II colorectal cancer.

J Gastrointest Oncol. 2021-8

[6]
[Application of preoperative serum CYFRA 21-1 level in the prognosis of colorectal cancer].

Zhonghua Yu Fang Yi Xue Za Zhi. 2023-10-6

[7]
Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.

BMC Cancer. 2022-9-8

[8]
[Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2017-4-25

[9]
Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.

Ann Surg Oncol. 2008-12

[10]
Preoperative Absolute Lymphocyte Count to Carcinoembryonic Antigen Ratio Is a Superior Predictor of Survival in Stage I to III Colorectal Cancer.

Clin Med Insights Oncol. 2022-9-26

本文引用的文献

[1]
Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.

JAMA Oncol. 2023-6-1

[2]
Predictive biomarkers of colon cancer immunotherapy: Present and future.

Front Immunol. 2022

[3]
Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis.

J Natl Cancer Inst. 2022-5-9

[4]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[5]
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.

J Clin Oncol. 2022-3-10

[6]
Ageing-related markers and risks of cancer and cardiovascular disease: a prospective study in the EPIC-Heidelberg cohort.

Eur J Epidemiol. 2022-1

[7]
Preoperative hemoglobin count and prognosis of esophageal cancer, a population-based nationwide study in Finland.

Eur J Surg Oncol. 2022-3

[8]
Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients.

Int J Mol Sci. 2021-7-27

[9]
PCSK9 and cancer: Rethinking the link.

Biomed Pharmacother. 2021-8

[10]
Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer.

Sci Rep. 2021-3-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索